Generative AI in Biopharma: A Complete Guide for Drug Development Teams
The biopharmaceutical industry stands at a critical juncture. Despite escalating R&D investments—often exceeding $2 billion per approved drug—productivity continues to decline, a phenomenon economists call Eroom's Law. Phase II and III clinical trial failure rates hover above 60%, and regulatory submission cycles stretch 18 to 24 months from database lock. Meanwhile, patent cliffs loom and biosimilar competition intensifies. Against this backdrop, a transformative technology has emerged: generative artificial intelligence. Unlike traditional AI models that classify or predict, generative systems create novel outputs—molecular structures, protocol designs, safety narratives—that can fundamentally reshape how we discover, develop, and commercialize therapeutics. For teams navigating discovery biology, translational medicine, clinical development operations, and regulatory affairs, understanding Generative AI in Biopharma has shifted from optional to essential. This guide provide...